Serotonin syndrome associated with clozapine withdrawal

JAMA Neurol. 2013 Aug;70(8):1054-5. doi: 10.1001/jamaneurol.2013.95.

Abstract

Importance: We describe a case of serotonin syndrome secondary to clozapine withdrawal and concomitant use of citalopram hydrobromide, a phenomenon that has been rarely reported.

Observations: This is a case report of a 47-year-old woman admitted to an academic medical center intensive care unit with coma, hypersalivation, hyperreflexia, and stimulus-induced clonus. The patient received a diagnosis of serotonin syndrome attributed to abrupt clozapine withdrawal with concomitant use of citalopram. She improved only minimally with supportive treatment (intravenous fluids, benzodiazapines, and withdrawal of selective serotonin-reuptake inhibitor) and received cyproheptadine hydrochloride on her third day of symptoms. Four hours after she received the loading dose of cyproheptadine, she was alert and oriented and at her baseline mental status, although some clonus remained.

Conclusions and relevance: Serotonin syndrome can result from the abrupt withdrawal of a 5-hydroxytryptamine receptor 2A antagonist from a treatment regimen that also includes a medication that increases serotonin availability.

MeSH terms

  • Benzodiazepines / therapeutic use
  • Citalopram / adverse effects*
  • Citalopram / therapeutic use
  • Clozapine / adverse effects*
  • Clozapine / therapeutic use
  • Cyproheptadine / therapeutic use
  • Female
  • Humans
  • Middle Aged
  • Selective Serotonin Reuptake Inhibitors / adverse effects*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Serotonin Antagonists / adverse effects*
  • Serotonin Antagonists / therapeutic use
  • Serotonin Syndrome / chemically induced*
  • Serotonin Syndrome / drug therapy
  • Substance Withdrawal Syndrome / complications*
  • Substance Withdrawal Syndrome / drug therapy
  • Substance Withdrawal Syndrome / etiology

Substances

  • Benzodiazepines
  • Citalopram
  • Clozapine
  • Cyproheptadine
  • Serotonin Antagonists
  • Selective Serotonin Reuptake Inhibitors